PotentialNet for Molecular Property Prediction
  The arc of drug discovery entails a multiparameter optimization problem
spanning vast length scales. They key parameters range from solubility
(angstroms) to protein-ligand binding (nanometers) to in vivo toxicity
(meters). Through feature learning---instead of feature engineering---deep
neural networks promise to outperform both traditional physics-based and
knowledge-based machine learning models for predicting molecular properties
pertinent to drug discovery. To this end, we present the PotentialNet family of
graph convolutions. These models are specifically designed for and achieve
state-of-the-art performance for protein-ligand binding affinity. We further
validate these deep neural networks by setting new standards of performance in
several ligand-based tasks. In parallel, we introduce a new metric, the
Regression Enrichment Factor $EF_\chi^{(R)}$, to measure the early enrichment
of computational models for chemical data. Finally, we introduce a
cross-validation strategy based on structural homology clustering that can more
accurately measure model generalizability, which crucially distinguishes the
aims of machine learning for drug discovery from standard machine learning
tasks.
